There is no cure to arrest or delay SBMA progression. It is estimated that
1000 individuals are affected by SBMA in Italy at any given time (prevalence: 1.5/100000) with an annual incidence of 0.19/100000 males. Here, we are going to test the potential of beta2-agonist stimulation on muscle as a therapeutic avenue for SBMA. We have provided pre-clinical evidence that β-agonist stimulation may be a therapeutic strategy for SBMA. Moreover, we have shown that beta2-agonists are effective in improving motor function without relevant adverse events in a small cohort of SBMA patients. To establish safety and efficacy of clenbuterol as a cure for SBMA, we are conducting a multicenter, phase II, randomized, double-blind, parallel-group, single dose, placebo-controlled trial. Indeed, based on our preliminary data, some concerns remain to be addressed.

开始日期2024-04-13

申办/合作机构

University Hospital Padova

NCT05692856 / RecruitingN/A

Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans: Myonuclear Addition, Hypertrophy and Myocellular Reprogramming

The purpose of the project is investigate muscle memory and underlying mechanisms in humans following resistance training and use of the anabolic substance clenbuterol.

开始日期2023-02-01

申办/合作机构

University of Copenhagen

NCT04094948 / Withdrawn临床2期IIT

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Stably Treated With Enzyme Replacement Therapy

The goals of this study are to determine safety and efficacy with regard to motor function of oral clenbuterol in combination with ERT in subjects with LOPD

开始日期2023-01-01

申办/合作机构

Duke University

100 项与盐酸克仑特罗相关的临床结果

登录后查看更多信息

100 项与盐酸克仑特罗相关的转化医学

登录后查看更多信息

100 项与盐酸克仑特罗相关的专利（医药）

登录后查看更多信息

1,914

项与盐酸克仑特罗相关的文献（医药）

2024-12-01·JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE

Phytogenic effects of Marrubium vulgare on the growth performance of weaned piglets: biochemical parameters and liquid chromatographic–electrospray ionization–mass spectrometric profile of plant and animal serum

Article

作者: Da Cunha, Guinter Silva ; Tizziani, Tiago ; Schlemper, Valfredo ; Sandjo, Louis P ; da Silva, Ana Caroline

Abstract:

BACKGROUND:

Multidrug‐resistant bacteria in humans have prompted the search for alternative solutions derived from herbal medicines that can substitute antibiotics in livestock production. Thus, the goal of this study was to evaluate the phytogenic properties of Marrubium vulgare infusion (MVI) on weaned pigs. Thirty animals were randomly divided into five groups of six animals, each receiving a physiological solution, clenbuterol and the infusion extract at doses of 0.01 (MVI 1%), 0.1 (MVI 10%) and 0.2 (MVI 20%) mg kg−1 for 28 days. Biochemical parameters and the liquid chromatographic–electrospray ionization–mass spectrometric (LC‐ESI‐MS) chemical profiles of the infusion extract and animal serum were studied.

RESULTS:

The doses MVI 1 and 10% led to weight gain higher than the controls. No significant changes were noted in the biochemical parameters including erythrocytes, hemoglobin, hematocrit, mean corpuscular volume and others. Evaluation of enzymatic levels in blood revealed no significant changes. LC‐ESI‐MS data of MVI showed the presence of 34 secondary metabolites, and successive chromatographic purification of MVI yielded marrubiin and apigenin as major components. LC‐ESI‐MS data of animal serum showed the presence of a diterpene, a flavonoid and diverse cholic acid derivatives.

CONCLUSION:

2024-11-01·ECOTOXICOLOGY

Toxicity of selected pharmaceuticals and their mixtures to the aquatic indicators Daphnia magna and Aliivibrio fischeri

Article

作者: Cambronero-Heinrichs, Juan Carlos ; Rodríguez-Rodríguez, Carlos E ; Montiel-Mora, José R ; Méndez-Rivera, Michael ; Ramírez-Morales, Didier

Despite the benefits derived from the use of pharmaceuticals, these compounds are currently considered contaminants of emerging concern because of their presence and persistence in the environment. This study aimed to determine the toxicity of 27 pharmaceuticals and the interaction effects of binary mixtures of selected compounds towards two model organisms: the microcrustacean Daphnia magna and the bacterium Aliivibrio fischeri (Microtox test). Six compounds, namely polymyxin B, polymyxin E, fluoxetine, diphenhydramine, clenbuterol and ketoprofen exhibited moderate toxicity towards D. magna. Additionally, three compounds (cefotaxime, polymyxin B, polymyxin E) also showed a moderate toxic effect on A. fischeri. The comparison of such results with model estimations showed inaccuracy in the predicted data, highlighting the relevance of experimental ecotoxicological assays. The assayed mixtures contained four selected drugs of high-hazard according to their reported concentrations in wastewater and surface water (diphenhydramine, trimethoprim, ketoprofen, and fluoxetine); data revealed interactions only in the fluoxetine-containing mixtures for D. magna, while all mixtures showed interactions (mostly synergistic) for Microtox. Chronic effects on the reproduction of D. magna were observed after exposure to fluoxetine and diphenhydramine, although higher sensitivity was determined for the latter, while the mixture of these compounds (which showed acute synergy in both models) also affected the reproduction patterns. Nonetheless, all the effects described at the acute or chronic level (for individual compounds or mixtures) were determined at concentrations higher than commonly reported at environmental levels. This work provides valuable ecotoxicological information for the risk assessment of pharmaceuticals and their mixtures in the environment.

2024-11-01·JOURNAL OF CHROMATOGRAPHY A

Two-dimensional metal-organic framework nanosheets coated solid-phase microextraction Arrow coupled with UPLC-Q-ToF-MS for the determination of three veterinary residues in milk and pork

Article

作者: Pan, Daodong ; Du, Xuanhua ; Lan, Hangzhen ; Wu, Zhen ; Wu, Yichun

This study presents a method utilizing solid-phase microextraction Arrow (SPME Arrow) combined with ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) for the selective detection of three veterinary drugs-thiabendazole, sulfamethazine, and clenbuterol-in milk and pork. Two-dimensional metal-organic framework nanosheets (2D-MOFs) were employed as coating materials for the SPME Arrow. Three types of 2D-MOFs (Ni, Mn, and Co based) were synthesized and characterized using Fourier transform infrared spectroscopy, scanning electron microscopy, transmission electron microscopy, and a physical adsorption analyzer. The 2D-MOF coatings were fabricated using the electrospinning technique, with polyacrylonitrile (PAN) serving as the binder. Comparative analysis of the three 2D-MOF coatings revealed that 2D-Ni-MOF was the optimal coating material for the SPME Arrow. Optimization of the coating preparation conditions and SPME procedures included determining the optimal mass ratio of 2D-Ni-MOF to PAN, electrospinning time, and extraction and desorption parameters. Equilibrium extraction was achieved within 60 min, and desorption was completed within 30 min. Subsequently, the 2D-Ni-MOF-SPME Arrow-UPLC-Q-TOF-MS method was established and validated under optimal conditions, demonstrating high precision with inter-day precision ranging from 3.8 % to 9.5 % and intra-day precision ranging from 5.1 % to 11.5 %. The reusability study indicated that the extraction performance of the new SPME Arrow remained consistent after 90 adsorption-desorption cycles. The method exhibited linearity in milk and pork over the ranges of 0.002-5 μg L^-1 and 0.01-5 μg L^-1, respectively. The detection limits in milk and pork were 0.001-0.004 μg L^-1 and 0.003-0.007 μg L^-1, respectively. This method demonstrated excellent applicability for determining residues of the three veterinary drugs in milk and pork.

项与盐酸克仑特罗相关的新闻（医药）

2024-10-12

·mobihealthnews

Springbok Analytics receives FDA 510(k) clearance for MuscleView

Springbok Analytics, a life sciences muscle and analytics company, has received FDA 510(k) clearance for MuscleView, an AI-powered technology that analyzes muscle health via magnetic resonance (MR) images. The AI-based technology analyzes MRI data and produces personalized 3D visualizations and metrics of muscle health. Springbok Analytics's full body muscle analysis capabilities were introduced initially for research purposes in 2023. According to Springbok, its technology was developed after more than 13 years of research and scientific validation. The aim of the AI technology is to alter complex magnetic resonance imaging (MRI) data produced from rapid scan protocols into simple 3D visualizations of someone's precise musculature thereby building a new standard in muscle health. In a statement, the company explained that AI accountable for muscle segmentation inside MuscleView was trained and tested on MRI scans generated across different patients, demographics as well as scan sites and MRI parameters such as manufacturer, magnetic field strength, series settings/types, matrix size, field of view and scan resolution. "Achieving FDA 510(k) clearance is a significant milestone for our company and a true testament to the integrity, diligence and collaboration our entire team has brought to Springbok every day over the last several years," Scott Magargee, chief executive officer and cofounder of Springbok Analytics, said in a statement. "This clearance is a key pillar to our commercialization strategy, allowing us to further integrate MuscleView and our cutting-edge muscle analytics into sports medicine, orthopedics, and therapeutic applications." THE LARGER TREND In July, Immunis, a clinical-stage biotech company partnered with Springbok Analytics to build a new standard in muscle health with its MRI-based AI muscle analysis technology that is utilized in elite sports, human performance and life sciences. Immunis is using Springbok’s technology to assess the effectiveness of its investigational secretome therapeutic, IMMUNA, in restoring muscle growth and function in a sarcopenic Phase 1/2a clinical trial population. In June, Springbok Analytics announced its participation in a Phase 1 Clinical Trial to analyze safe dosage for clenbuterol that is used as a treatment for Facioscapulohumeral muscular dystrophy (FSHD). Springbok's MRI-based muscle analysis aids researchers in better understanding and identifying disease progression of FSHD by providing individual muscle volume and fat fraction metrics in clinical trial participants.

临床1期临床申请

2024-06-12

·PRNewswire

Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment

This dose escalation study for safety and tolerability of clenbuterol incorporates Springbok's precision muscle MRI analysis and molecular outcome measures CHARLOTTESVILLE, Va., June 12, 2024 /PRNewswire/ - Springbok Analytics (), a life sciences muscle analytics company, announced today its participation in a Phase 1 Clinical Trial to evaluate safe dosage for clenbuterol as a treatment for Facioscapulohumeral muscular dystrophy (FSHD). Springbok's MRI-based muscle analysis helps researchers to better understand and identify disease progression of FSHD by providing individual muscle volume and fat fraction metrics in trial participants. Beyond studying the safety and tolerability of clenbuterol, Springbok is focused on strengthening and extending the foundations for future FSHD clinical trial design and execution. Springbok is also supporting the 31st Annual FSHD Society International Research Congress held this week in Denver. This trial is part of a larger NIH Wellstone grant led by Jeff Chamberlain, MD and Stephen Tapscott, MD, PhD, with trial activities coordinated by Jeffrey M. Statland, MD and Rabi Tawil, MD, who direct the FSHD Clinical Trials Research Network (CTRN) out of the University of Kansas and the University of Rochester, respectively. Seth Friedman, PhD at Seattle Children's is overseeing imaging implementation. "We are excited to expand the scope of our work with Springbok Analytics. This technology can benefit an FSHD-focused clinical trial by giving us new perspectives on what can be modulated by drug therapy," said Dr. Friedman. "The shorter exam duration will improve patient tolerability and Springbok's comprehensive individual muscle analytics get us closer to deriving personalized progression models." FSHD is one of the most prevalent muscular dystrophies, affecting an estimated 20,000 people in the United States alone. There are currently no FDA approved therapies for FSHD, which represents both a large and unmet medical need. Clenbuterol has been shown to decrease DUX4-related targets in patient-derived FSHD cell assays, and several small studies in neuromuscular disorders have demonstrated improved strength or function with clenbuterol. Springbok's AI advancements have also led to improvements in both imaging and processing time. A recent study focused on the disease burden of FSHD clinical trial participants1 highlighted a strong preference for imaging over invasive muscle biopsies, which often remove healthy muscle tissue, as well as the need to reducing imaging time. 85 percent of the FSHD patients surveyed said that they would be willing to take part in MRI, compared to just 44 percent for an open muscle biopsy. For participants that indicated they would be willing to undergo an MRI, just 30 percent said they would be willing to sit in an MRI machine for two hours or more. Springbok's full body analysis can be done in under 40 minutes, and its protocols have been designed with scalability in mind, knowing that flexibility and ease-of-deployment are requirements across global multi-site studies. "The rationale for this trial is that if clenbuterol is safe and well tolerated, and can increase muscle mass and reduce DUX4 levels, it can be repurposed to both stop disease progression and restore motor function," said Jeffrey M. Statland, MD, professor of neurology at the University of Kansas Medical Center. "Springbok's precision and sensitivity are so important in studying a disease like FSHD, which impacts the form and function of individuals, and their specific muscles, so differently." Springbok scans are also accompanied by patient-facing reports with 3D muscle visualizations, empowering individuals to better manage their muscle health and disease progression. "The patient experience in clinical trials is always important, especially when there are accessibility issues. From what we have heard from many FSHD patients, length of time in the scanner and lack of reporting are factors of consideration in trial participation," said Scott Magargee, Springbok Analytics Co-Founder and CEO. "We are helping researchers and pharmaceutical companies to run more effective clinical trials by generating more precise and personalized insights, supporting those on the leading edge of FSHD research pursuing improved treatments, and ultimately, a cure." Springbok's flexible imaging protocol has been implemented at hundreds of imaging centers around the world and is compatible across all major scanner platforms. The company is also developing standardized guidance for how to use muscle MRI as a trial passport to screen for drug trial enrollment. The FSHD Clinical Trial Research Network (CTRN) is being leveraged as part of this trial, and the data is intended to ultimately support a Phase 3 trial to confirm the efficacy of Clenbuterol in FSHD. To learn more about Springbok's muscle analysis capabilities for clinical trials, visit here. About Springbok Analytics: Springbok is a life sciences muscle analytics company that drives better health and performance outcomes. Its technology analyzes MRI data and creates personalized 3D visualizations of muscle health, enhancing the assessment, treatment monitoring, research and diagnostic value of advanced imaging. Springbok's rapid imaging sequence and AI-based analysis reveals a complete view of musculoskeletal health, precisely quantified individual muscle volume and quality, fat infiltration, left-right asymmetries, as well as scar tissue, edema, and tendon morphology. To learn more about how Springbok is creating a better view of health, please visit . SOURCE Springbok Analytics

临床1期

2024-03-21

·药通社

2024年，这些药品可能被集采（附清单）

2018年以来，国家医保局已组织开展九批国家组织药品集采，共纳入374种药品，平均每批国采纳入41个品种左右，第五批国采品种数量最多达到61个。故推测，第十批国采的化药品种数可能在41-61个。第九批中选和执行时间预计在今年3月执行，如果按此时间推算，第十批国采将在今年上半年开始。截至2024年2月26日，已经有120个品种满足“原研+过评”企业≥5家的竞争格局。第十批集采预测品种序号药品名称医保剂型规格过评+原研1磷酸西格列汀片口服常释剂型0.1g、25mg、50mg、100mg22+12地氯雷他定口服溶液口服液体剂0.5g：2.5mg、1g：5mg、100ml:50mg、10ml：5mg、120ml：60mg、150ml：75mg、30ml：15mg、50ml：25mg、60ml：30mg16+03苯甲酸阿格列汀片口服常释剂型12.5mg、25mg、6.25mg、12.5mg、25mg12+14哌柏西利胶囊口服常释剂型0.125g、0.1g、75mg、100mg、125mg11+15阿普米司特片口服常释剂型10mg、20mg、30mg10+16氨溴特罗口服溶液口服液体剂60ml：盐酸氨溴索90mg与盐酸克仑特罗60μg、100ml：盐酸氨溴索150mg与盐酸克仑特罗100μg、1ml：盐酸氨溴索1.5mg与盐酸克仑特罗1μg11+07氢溴酸伏硫西汀片口服常释剂型10mg、20mg、5mg10+18阿司匹林肠溶片口服常释剂型0.1g、0.3g、100mg9+19达格列净片口服常释剂型10mg、5mg9+110拉米夫定片口服常释剂型0.15g、0.1g、0.3g9+111沙库巴曲缬沙坦钠片口服常释剂型50mg（沙库巴曲24mg/缬沙坦26mg）、100mg（沙库巴曲49mg/缬沙坦51mg）、200mg（沙库巴曲97mg/缬沙坦103mg）9+112盐酸美金刚口服溶液口服液体剂100ml：1g、120ml：0.24g、50ml：0.5g9+013普瑞巴林口服溶液口服液体剂100ml：2g、200ml：4g、473ml：9.46g9+014碳酸司维拉姆片口服常释剂型0.8g8+115盐酸左西替利嗪口服滴剂口服液体剂10ml：50mg、15ml：75mg、20ml：0.1g、150ml：75mg、75ml：37.5mg9+016利格列汀片口服常释剂型5mg7+117索磷布韦片口服常释剂型0.4g7+118利培酮口服液口服液体剂0.001、30ml:30mg、0.1%(30ml:30mg)、0.1%(100mL:100mg)6+119磷酸特地唑胺片口服常释剂型0.2g5+120叶酸片口服常释剂型5mg6+021环孢素软胶囊口服常释剂型10mg、25mg、50mg、100mg4+122阿仑膦酸钠片口服常释剂型10mg、70mg4+123阿瑞匹坦胶囊口服常释剂型0.125g、80mg、120mg4+124艾曲泊帕乙醇胺片口服常释剂型25mg4+125艾司唑仑片口服常释剂型1mg、2mg5+026吡拉西坦片口服常释剂型0.4g、0.8g5+027丙戊酸钠口服溶液口服液体剂100ml：4g、300ml：12g4+128地诺孕素片口服常释剂型2mg4+129依帕司他片口服常释剂型50mg7+030艾地骨化醇软胶囊口服常释剂型0.5μg、0.75μg5+131重酒石酸卡巴拉汀胶囊口服常释剂型1.5mg、3mg、6mg5+132乙磺酸尼达尼布软胶囊口服常释剂型0.15g、0.1g6+033泊沙康唑肠溶片口服常释剂型0.1g5+134盐酸伐地那非片口服常释剂型5mg、10mg、20mg4+135酒石酸伐尼克兰片口服常释剂型0.5mg、1mg4+136盐酸非索非那定片口服常释剂型30mg、60mg、120mg、180mg4+137福多司坦口服溶液口服常释剂型100ml：8g、120ml：9.6g、500ml：40g、50ml：4g、5ml：0.4g5+038卡马西平片口服常释剂型0.1g、0.2g4+139口服补液盐散（Ⅲ）口服散剂5.125g5+040甲磺酸雷沙吉兰片口服常释剂型1mg4+141富马酸卢帕他定片口服常释剂型10mg4+142螺内酯片口服常释剂型0.1g、20mg、25mg5+043氯雷他定糖浆口服液体剂100ml：0.1g、1ml：1mg、60ml：60mg4+144瑞戈非尼片口服常释剂型40mg4+145替米沙坦氢氯噻嗪片口服常释剂型每片含替米沙坦40mg，氢氯噻嗪12.5mg、每片含替米沙坦80mg和氢氯噻嗪12.5mg4+146托伐普坦片口服常释剂型15mg、30mg5+047维生素B2片口服常释剂型5mg5+048硝酸甘油片口服常释剂型0.5mg5+049盐酸伊托必利片口服常释剂型50mg4+150左炔诺孕酮片口服常释剂型0.75mg、1.5mg4+151米拉贝隆缓释片缓释控释剂型25mg、50mg6+152枸橼酸托法替布缓释片缓释控释剂型11mg6+153左乙拉西坦缓释片缓释控释剂型0.5g、0.75g5+054曲伏前列素滴眼液滴眼剂0.4ml:16μg、2.5ml:0.1mg、2.5ml:0.075mg5+255溴芬酸钠滴眼液滴眼剂0.4ml:0.4mg、5ml:5mg6+156普拉洛芬滴眼液滴眼剂5ml：5mg4+157吸入用乙酰半胱氨酸溶液吸入剂3ml：0.3g11+158吸入用七氟烷吸入剂120ml、250ml6+259他克莫司软膏软膏剂10g:10mg、10g:3mg、0.1%(10g:10mg)、0.03%(10g:3mg)7+160乙酰半胱氨酸泡腾片其他0.6g5+161舒更葡糖钠注射液注射液2ml：0.2g、2ml：200mg、5ml：500mg16+162间苯三酚注射液注射液4ml：40mg14+063注射用哌拉西林钠注射剂0.5g、1g、2g、3g、4g13+064胞磷胆碱钠注射液注射剂2ml：0.1g、2ml：0.25g、4ml：0.5g10+065拉考沙胺注射液注射剂20ml：0.2g、10mg/ml9+166帕拉米韦注射液注射剂15ml：0.15g、20ml：0.2g、60ml：0.3g10+067泊沙康唑注射液注射剂16.7ml：0.3g9+168复方碳酸氢钠电解质注射液注射剂500ml、1000ml10+069注射用氨苄西林钠舒巴坦钠注射剂0.75g、1.5g、2.25g、3g7+170注射用氨苄西林钠舒巴坦钠注射剂0.5g、1g、2g8+071醋酸钠林格注射液注射剂500ml8+072氟尿嘧啶注射液注射剂10ml：0.25g、10ml：0.5g、20ml：1g8+073羟乙基淀粉130/0.4氯化钠注射液注射剂250ml:15g:2.25g、500ml:30g:4.5g、500ml:30g7+174氨茶碱注射液注射剂10ml:0.25g、0ml:0.25g、2ml:0.25、20ml:0.5g、2ml:0.5g、7+075氨基己酸注射液注射剂10ml:2g、20ml:4g、20ml:5g、8ml:2g7+076低钙腹膜透析液(乳酸盐-G1.5%）注射剂2000ml7+077低钙腹膜透析液(乳酸盐-G2.5%注射剂2000ml、2500ml7+078注射用拉氧头孢钠注射剂0.25g、0.5g、lg7+079注射用盐酸罗沙替丁醋酸酯注射剂75mg7+080乳酸钠林格注射液注射剂500ml6+081注射用醋酸西曲瑞克注射剂0.25ms5+182注射用右雷佐生注射剂0.25g、0.5g6+083硫酸阿米卡星注射液注射剂1ml：0.1g、2ml：0.2g5+084达肝素钠注射液注射剂0.2ml：2500IU、0.2ml：5000IU、0.3ml：7500IU、4+185注射用尼可地尔注射剂12mg、2mg、48mg7+086硫酸特布他林注射液注射剂1ml:0.5mg、5ml:2.5mg7+087地高辛注射液注射剂1ml:0.1mg、2ml:0.5mg、6+088乳酸环丙沙星氯化钠注射液注射剂100ml:0.2g、200ml:0.4g5+189左西孟旦注射液注射剂5ml:12.5mg5+190己酮可可碱注射液注射剂5ml:0.1g6+091卡前列素氨丁三醇注射液注射剂1ml:0.25mg5+192注射用青霉素钠注射剂100万IU、160万IU、400万IU、40万IU、500万IU、800万IU、80万IU6+093重酒石酸去甲肾上腺素注射液注射剂1ml:2mg、4ml:8mg6+094盐酸多巴酚丁胺注射液注射剂1.6ml：20mg、20ml：0.25g、40ml：0.5g、5ml：0.1g5+095盐酸多柔比星脂质体注射液注射剂10ml：20mg、25ml：50mg、5ml：10mg5+096注射用福多匹坦双葡甲胺注射剂0.15g5+097腹膜透析液（乳酸盐-G1.5%）注射剂2000ml5+098腹膜透析液（乳酸盐-G2.5%）注射剂2000ml5+099钆布醇注射液注射剂7.5ml：4.5354g、1:4.5354g、15ml：9.0708g4+1100盐酸格拉司琼注射液注射剂1ml：1mg、3ml：3mg5+0101重酒石酸间羟胺注射液注射剂1ml：10mg5+0102盐酸林可霉素注射液注射剂10ml：3g、2ml：0.6g5+0103氯化钾注射液注射剂10ml：1.5g、10ml：1g、20ml：3g5+0104盐酸纳洛酮注射液注射剂10ml：4mg、1ml：0.4mg、1ml：1mg、2ml：2mg5+0105盐酸曲马多注射液注射剂1ml：50mg、2ml：0.1g、2ml：50mg4+1106去氨加压素注射液注射剂1ml：13.35μg、1ml：15μg、1ml：3.56μg、1ml：4μg4+1107注射用头孢哌酮钠注射剂0.5g、1g、1.5g、2g、3g5+0108注射用头孢他啶阿维巴坦钠注射剂2.5g4+1109盐酸戊乙奎醚注射液注射剂1ml：0.5mg、1ml：1mg、2ml：2mg4+1110硝酸异山梨酯注射液注射剂10ml：10mg、5ml：5mg4+1111注射用亚胺培南西司他丁钠注射剂0.5g、1g4+1112小儿盐酸氨溴索滴剂口服液体剂50ml：0.75g15+0盐酸氨溴索滴剂20ml：0.3g、50ml：0.75g盐酸氨溴索口服溶液100ml：0.3g、100ml：0.6g、10ml：30mg、10ml：60mg、5ml：15mg、5ml：30mg113盐酸艾司洛尔注射液注射剂10ml：0.g、250ml：2.5g：1.475g12+0盐酸艾司洛尔氯化钠注射液100ml：2g：0.41g、50ml：1g：0.205g、2ml：0.2g114布洛芬混悬滴剂口服液体剂20ml：0.8g9+0布洛芬混悬液100ml：2g、30ml：0.6g115低钙腹膜透析液（乳酸盐-G1.35%）注射剂2000ml、2500ml9+0低钙腹膜透析液（乳酸盐-G4.25）2000ml腹膜透析液（乳酸盐）（低钙）2000ml116平衡盐溶液(供灌注用)外用液体剂250ml、500ml、7+1平衡盐冲洗液1000ml平衡盐眼内灌洗液15ml117西格列汀二甲双胍片口服常释剂型——6+1西格列汀二甲双胍片(I)磷酸西格列汀50mg(以游离碱计)和盐酸二甲双胍500mg西格列汀二甲双胍片(Ⅱ)磷酸西格列汀50mg(以游离碱计)和盐酸二甲双胍850mg、118盐酸安非他酮缓释片缓释控释剂型0.1g、0.15g、0.2g5+1盐酸安非他酮缓释片(Ⅱ)0.15g、0.3g119拉莫三嗪分散片口服常释剂型25mg、50mg5+1拉莫三嗪片0.1g、25mg、50mg、100mg120双氯芬酸钠缓释片缓释控释剂型0.1g、75mg5+0双氯芬酸钠缓释胶囊（Ⅰ）0.1g推荐阅读制剂/改良新药/立项/MAH/CXO/药品注册，报名get这场大会！↓

IPO

100 项与盐酸克仑特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01360	盐酸克仑特罗	R03AC14 R03CC13	DB01407

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性支气管炎	日本	Teijin Pharma Ltd.	1995-06-30
压力性尿失禁	日本	Teijin Pharma Ltd.	1995-06-30
慢性支气管炎	日本	Teijin Pharma Ltd.	1986-06-19
哮喘	中国	成都第一制药有限公司	1981-01-01
支气管炎	中国	成都第一制药有限公司	1981-01-01
肺气肿	中国	成都第一制药有限公司	1981-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
面肩肱型肌营养不良	临床1期	美国	Springbok, Inc.	2024-06-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04245709 (CTgov)	临床2期	肌萎缩侧索硬化	25	Clenbuterol	鑰選觸鏇餘醖獵繭顧夢(廠夢壓鏇鏇構夢網簾鑰) = 顧壓餘襯廠憲艱窪範鹹願窪鏇廠獵糧獵憲觸襯 (鬱糧齋製選廠淵獵觸積, 遞餘鬱築網願選鬱鑰製 ~ 積餘積獵廠膚壓鏇艱顧) 更多	-	2022-09-06
NCT01942590 (Pubmed \| Mol Ther)	临床1/2期	II型糖原贮积病	17	Clenbuterol	願膚繭鏇艱鹹醖繭餘廠(鏇顧窪壓糧構鬱鹽窪遞) = 遞餘繭遞夢簾範顧壓願獵壓積顧繭餘積廠築網 (廠製蓋膚鏇壓鏇積衊壓 ) 更多	积极	2018-09-05
NCT00585546 (HARPS, CTgov)	临床1期	扩张型心肌病 \| 难治性心力衰竭	18	clenbuterol	選醖繭鏇齋願顧鹹壓蓋(憲鏇壓網鹽艱觸選顧廠) = 廠獵夢餘顧衊襯壓獵醖糧餘鏇鬱壓衊鬱窪獵遞 (鬱鬱鬱淵憲獵築糧襯製, 夢顧鏇構齋廠顧願鹽糧 ~ 膚餘顧選築鑰憲製窪構) 更多	-	2017-12-15
NCT01942590 (CTgov)	临床1/2期	II型糖原贮积病	17	Clenbuterol (Clenbuterol)	構範製構觸壓鏇窪願醖(積壓壓願構範糧憲鹽憲) = 齋醖顧廠淵窪顧構鏇衊壓繭齋艱窪獵衊遞願蓋 (鑰選蓋製鬱醖願繭衊築, 範鹽憲築製觸鹽顧築醖 ~ 艱廠顧顧範鏇顧築觸鏇) 更多	-	2017-10-23
NCT01942590 (CTgov)	临床1/2期	II型糖原贮积病	17	Placebo (Placebo Comparator)	構範製構觸壓鏇窪願醖(積壓壓願構範糧憲鹽憲) = 衊憲襯鹹遞簾憲襯廠衊壓繭齋艱窪獵衊遞願蓋 (鑰選蓋製鬱醖願繭衊築, 觸鑰鹽憲鹽糧鏇選積餘 ~ 構醖糧醖淵獵築膚願選) 更多	-	2017-10-23